New guidelines, growth opportunities, and investment in new technologies

Our Press & Policy

Stay up to date with the latest IVD sector news and developments in health policy.


OncoHelix and Oxford Cancer Biomarkers Enter into a Partnership to Offer Breakthrough Cancer Genetic Screening Test to Canadians

20 Mar, 2023 | Return|

OXFORD, UK – 20th March 2023 – Oxford Cancer Biomarkers (OCB) and OncoHelix today announce a new partnership to offer OCB’s advanced genetic test in Canada for screening and detection of people at risk for colorectal cancer. Based on ground-breaking research at the University of Oxford, this screening test was identified by analysis of a series of large, collaborative studies, involving more than 100,000 individuals and detects several specific point mutations in a person’s genetic code that are associated with an increased risk of developing colorectal cancer.


Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second leading cause of cancer death worldwide. However, CRC is largely preventable and curable if detected early through screening. Screening for CRC is recommended for average-risk individuals starting at age 40 and continuing until age 75, especially those with a family history of cancer, as well as those who have previously had cancer or other health conditions that may increase their risk of developing cancer.


OCB’s CRC screening test will help signpost opportunities to make early modifications to lifestyle and commit to regular screenings that can help offset an increased risk and could help diagnose colorectal cancer at the earliest opportunity. The test will complement existing cancer screening programs and will be available through OncoHelix’s network of partners providing direct-to-consumer (DTC) testing in Canada. The test will be available for Canadians in the summer of 2023.


David Kerr CBE FRCP FMedSCi, OCB Director and Prof of Cancer Medicine, University of Oxford says, ‘After a professional lifetime of treating patients with advanced colorectal cancer, I see the extraordinary potential of this genetic test to reduce the number of patients who develop this disease and to detect cancer at an earlier stage when there is a much greater likelihood that tumour can be cured by surgery. It will not replace current screening programs for colorectal cancer, but will be a significant value add, identifying at-risk individuals for more intensive surveillance.’


“We are thrilled to partner with OCB and take a significant step forward in our journey to offer cutting-edge molecular tests for cancer screening to Canadians. This partnership underscores our commitment to providing the latest advancements in cancer diagnostics to our patients and healthcare professionals. OCB’s genetic test will allow early and accurate identification of Canadians at higher risk of developing colorectal cancer, thus allowing timely intervention and prompt pre-emptive lifestyle changes.” Says Dr Faisal Khan, CEO, OncoHelix, and Associate Professor at the University of Calgary.


Dr Pinaki Bose, VP, Planning and Management, OncoHelix, and Assistant Professor at the University of Calgary Says, “Joining forces in Canada with a reputed organization like OCB will allow us to expand the battery of genomic tests accessible directly to consumers in Canada. This critical cancer screening genetic test will nicely complement our comprehensive genomic profiling panels already serving Canadians.” The partnership between OncoHelix and OCB represents an important step forward in the fight against cancer, offering Canadians access to the latest advancements in personalized cancer diagnosis and a commitment to improving patient outcomes in colorectal cancer.


About Oxford Cancer Biomarkers Ltd (OCB) Oxford Cancer Biomarkers (OCB) is a spin-out from the University of Oxford, developing and commercialising a suite of AI-enabled diagnostic tools that harness the analytical capabilities of digital pathology and pharmacogenomic markers to optimise cancer treatment pathways. OCB continues to expand its portfolio with novel biomarkers and proprietary algorithms that enable clinicians to make personalised treatment recommendations based on real-world evidence and empower patients to make better-informed decisions about their own cancer therapy. For more information, please visit




For further information please contact:

Oxford Cancer Biomarkers Ltd

Tel: +44 1865 784743

Nadia Whittley, CEO

Interested in becoming a member? Join us!

Copyright 2024 BIVDA Ltd is registered in England
Company Number 2687137
Registered Office is 299 Oxford Street (5th floor),
London, W1C 2DZ. VAT Number 563105858